Regenxbio Inc. (RGNX) Sees Unusually-High Trading Volume
Shares of Regenxbio Inc. (NASDAQ:RGNX) saw unusually-high trading volume on Tuesday . Approximately 497,432 shares changed hands during trading, an increase of 85% from the previous session’s volume of 268,925 shares.The stock last traded at $7.90 and had previously closed at $7.99.
RGNX has been the subject of a number of research reports. Chardan Capital restated a “buy” rating on shares of Regenxbio in a research report on Tuesday, May 10th. Piper Jaffray Cos. restated a “buy” rating and set a $33.00 target price on shares of Regenxbio in a research report on Tuesday. Zacks Investment Research lowered shares of Regenxbio from a “hold” rating to a “sell” rating in a research report on Tuesday, March 22nd. Finally, Morgan Stanley increased their price objective on shares of Regenxbio from $34.00 to $36.00 in a research report on Friday, April 8th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $28.35.
The company’s 50-day moving average is $10.74 and its 200-day moving average is $12.19. The firm’s market capitalization is $212.15 million.
Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.01. Equities research analysts forecast that Regenxbio Inc. will post ($2.37) EPS for the current fiscal year.
In other news, insider Fmr Llc sold 18,300 shares of Regenxbio stock in a transaction that occurred on Tuesday, May 17th. The shares were sold at an average price of $12.41, for a total transaction of $227,103.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).